News

National Institute for Health and Care Excellence1d
Chronic heart failure in adults: diagnosis and management
You can now review and comment on this draft guideline. The consultation closes on Tuesday 08 July 2025 at 5pm. In line with NICE’s commitment to incorporate technology appraisals (TAs) within ...
The National Institute for Health and Care Excellence4d
10 Year Health Plan empowers NICE to get patients better care, faster
The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...
National Institute for Health and Care Excellence5d
1 Recommendations | Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347] | Obecabtagene autoleucel for treating relapsed or ...
Obecabtagene autoleucel (obe‑cel) should not be used to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia in adults.
National Institute for Health and Care Excellence7d
NICE newsletters and alerts
Subscribe to our newsletters, alerts and awareness service. Keep up to date with the latest evidence based information across health and social care.
National Institute for Health and Care Excellence19d
Appeal | Project documents | Cemiplimab with platinum-based ...
Notice of Appeal Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] NICE has received 1 appeal, that falls within one or more of the two strictly ...
National Institute for Health and Care Excellence20d
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS | NICE
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...
National Institute for Health and Care Excellence20d
Overview | Atezolizumab for adjuvant treatment of resected non-small ...
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...
National Institute for Health and Care Excellence20d
Overview | Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | Guidance | NICE
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its ...
National Institute for Health and Care Excellence20d
4 Evaluation committee members and NICE project team | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered as a streamlined evaluation by the lead team of committee D, which includes the chair, vice ...
National Institute for Health and Care Excellence20d
Resource impact summary report | Tools and resources | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults ...
National Institute for Health and Care Excellence20d
Overview | Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | Guidance | NICE
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers. Last reviewed: 19 June 2025 Guidance development process LSA guidance evaluates categories of ...